Sociedad Americana de Hirudoterapia

Correction to: Draft genome sequences of Hirudo medicinalis and salivary transcriptome of three closely related medicinal leeches

Correction notice published in BMC Genomics (2020)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportGenómica y proteómicaFarmacología salivalBabenko VV et al. · BMC genomics, 2020

Abstract

An amendment to this paper has been published and can be accessed via the original article.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticlePublished Erratum

Resumen

Correction to the foundational Hirudo medicinalis draft genome and salivary transcriptome of H. medicinalis, H. orientalis, and H. verbana. Updates supplementary files and accession numbers.

Por qué esto importa para la hirudoterapia

This published erratum notice contains only a single statement: that an amendment to the original paper has been published and can be accessed via the original article. The abstract provides no substantive scientific data, no findings, no methodological details, and no information about genome sequences, salivary transcriptomes, or any leech-related content. Because the abstract is devoid of any standalone content, this item offers no direct scientific value for the domain of hirudotherapy or the leech secretome. The original article and its correction would need to be consulted directly for any relevant information.

Citación

Correction to: Draft genome sequences of Hirudo medicinalis and salivary transcriptome of three closely related medicinal leeches.

Babenko VV et al. · BMC genomics, 2020

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.